Myeloma-related disorder (MRD) is an uncommon disease in cats, for which there is no established standard of care. In this retrospective study, we evaluated presentation, response to treatment, and toxicity in cats with MRD receiving systemic treatment. Previously reported prognostic factors were evaluated for their impact on survival in cats receiving chemotherapy. Of fifteen cases identified, thirteen received melphalan or cyclophosphamide +/- corticosteroids as first-line therapy. Chlorambucil was commonly used as rescue therapy in cats with progressive disease, or in cases of chemotherapy-related toxicity with first line agents. Overall response rates were 71% and 83% for melphalan- and cyclophosphamide-treated cats, respectively. Discontinuation of melphalan due to toxicity was common. Survival times for cats initially treated with melphalan or cyclophosphamide were not significantly different (median 252 and 394 days, respectively), and no statistically significant prognostic factors were identified. This study suggests that the combination of cyclophosphamide and corticosteroids is well tolerated and may be considered as first-line therapy for cats with systemic MRD.
Skip Nav Destination
Article navigation
July/August 2015
CASE SERIES|
July 01 2015
Clinical Signs, Treatment, and Outcome in Cats with Myeloma-Related Disorder Receiving Systemic Therapy
Claire M. Cannon, BVSc;
Claire M. Cannon, BVSc
From the Department of Veterinary Clinical Sciences, College of Veterinary Medicine (C.C., A.B.) and School of Statistics (C.K.), University of Minnesota, Saint Paul, MN.
*Claire M. Cannon's present affiliation is Department of Small Animal Clinical Sciences, University of Tennessee, Knoxville, TN.
Search for other works by this author on:
Christina Knudson, BA;
Christina Knudson, BA
From the Department of Veterinary Clinical Sciences, College of Veterinary Medicine (C.C., A.B.) and School of Statistics (C.K.), University of Minnesota, Saint Paul, MN.
Search for other works by this author on:
Antonella Borgatti, MS, DVM
Antonella Borgatti, MS, DVM
From the Department of Veterinary Clinical Sciences, College of Veterinary Medicine (C.C., A.B.) and School of Statistics (C.K.), University of Minnesota, Saint Paul, MN.
*Claire M. Cannon's present affiliation is Department of Small Animal Clinical Sciences, University of Tennessee, Knoxville, TN.
Search for other works by this author on:
J Am Anim Hosp Assoc (2015) 51 (4): 239–248.
Citation
Claire M. Cannon, Christina Knudson, Antonella Borgatti; Clinical Signs, Treatment, and Outcome in Cats with Myeloma-Related Disorder Receiving Systemic Therapy. J Am Anim Hosp Assoc 1 July 2015; 51 (4): 239–248. doi: https://doi.org/10.5326/JAAHA-MS-6216
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionCiting articles via
Long-Term Survival of Primary Intracranial Histiocytic Sarcoma Through Surgical Resection and Low-Dose CCNU
Kyosuke Hidari, DVM, Yuya Nakamoto, DVM, PhD, James K. Chambers, DVM, PhD, Kazuyuki Uchida, DVM, PhD, Isao Mori, DVM, Miwa Nakamoto, DVM
Microfilaria in the Urine of a Dog with Concurrent Urinary Bladder Sarcoma
Nicole Schlette, DVM, Erin Burton, DVM, MS, DACVP, Amber Harris, DVM, DACVIM (Internal Medicine), Kendall Langsten, DVM, DACVP, Erik Olson, DVM, PhD, DACVP, Daniel Heinrich, DVM, DACVP
Chronic Myelomonocytic Leukemia with Central Nervous System Involvement in a Dog
Ilaria Tartari, DVM, Fabio Tocco, DVM, Giorgio Cancedda, DVM, Veronica Angioni, DVM, Marco Podda, DVM, Antonella Gallucci, DVM, PhD, DECVN, EBVS
Treatment Outcomes of Canine Orbital Meningiomas in Seven Cases
Akihiro Uno, DVM, Ryota Iwasaki, DVM, PhD, Takashi Mori, DVM, PhD
Transient Hypoadrenocorticism in a 7-Week-Old Kitten
Alba Planas Vintro, BVM, Linda G. Martin, DVM, MS, DACVECC, Cassidy L. Cordon, DVM, Sabrina N. Hoehne, Dr. med. vet., DACVECC, DECVECC, Elizabeth B. Davidow, DVM, DACVECC